Board of Directors
The board comprises members with exceptional experience in science, venture finance and management of biotech enterprises.
Sarah Howell, Ph.D
Dr. Howell has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas having served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had full responsibility for CMC development and supply across BTG’s diverse portfolio of clinical and commercial products. Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline. She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee. Dr. Howell has an honours degree in Chemistry from the University of Birmingham and a PhD in Physical Organic Chemistry from the University of St Andrews.
Andrew J M Richards, Ph.D, CBE (Chairman)
Andy is an established biotechnology entrepreneur and business angel with broad experience of the UK biotechnology sector in research, drug development and in building commercial relationships. He is the Chairman of Ixico plc, Congenica Ltd, Novacta Biosystems Ltd and Cambridge Temperature Concepts Ltd, a Non-Executive Director of Babraham Bioscience Technology Ltd, Iseo Ltd (formerly Psychology On-Line), Cancer Research Technology Ltd (the commercial arm of Cancer Research UK), and a Trustee of the British Science Association. Andy is a Cambridge graduate with a PhD in enzyme chemistry and was a founder of Chiroscience in 1992 and an executive director through to the Celltech deal in 1999. Andy has a track record as a founder, active investor in and director of more than 20 innovative healthcare and life-science companies
Andrew Lane, MA
Andrew joined Unilever as a marketing trainee in 1985 after studying Biochemistry at Cambridge University. He is a founding Director of Unilever Ventures which focuses on investments in Home and Personal Care Technology. He has been involved as a Director in the set-up and development of three other life science businesses (BAC BV, Pharmakodex Ltd, and Insense Ltd).
Alan E Smith, Ph.D, FRS, CBE
Alan is the former Senior Vice President and the Chief Scientific Officer of Genzyme Corporation, Cambridge MA, where he had overall responsibility for the company’s science. Prior to is acquisition by Genzyme in 1989, Alan was the vice president and scientific director of Integrated Genetics, a MA start-up biotechnology company. From 1980 - 84 he was head of the biochemistry division at the National Institute of Medical Research, Mill Hill, London. Presently Alan sits on the Scientific Advisory Boards of the Cancer Research Institute in Cambridge UK, of Pharnext, a start up genomics company in Paris, France and of ImmuneXcite, a start-up immunology company, in Lexington MA. He is on on the Board of Directors of Advantagene a start-up gene therapy company in Newton MA.
He is chairman of the Board of Cambridge in America, the representative body of the University and Colleges of Cambridge in North America. Alan has published extensively on the genetic code and protein synthesis, tumour virology, cell biology and cystic fibrosis. He holds a B.A. from Christ’s College, Cambridge and a Ph.D. from the Laboratory of Molecular Biology, Cambridge, England. He is a fellow of the Royal Society of London and of Christ’s College.
Ian has a broad experience within the life science industry covering biotech, medtech and nutrition. He has been with DSM Venturing since 2008, investing in Europe, US and Israel. He is today more focused upon life science and material science investments within Europe and Israel. ian has over 23 years' experience in life scicence and technology driven companies, 16 years of which being within the pharmaceutical industry, addressing both innovative biotechn companies as well as global pharma companies. Prior to joining DSM Venturing he ran an internal start-up supplying earlly stage clinical material.
He is currently a board member of Arecor, Regentis, Essential Medical, Isobionics, nutriLeads, BioProcess Control and NovoPolymers.
Thomas Reese Saylor, MBA
Tom has a background in management, strategy development, deal negotiation and fundraising for entrepreneurial biopharma companies. He was the CEO of Sirus Pharmaceuticals Limited, a company developing drugs based upon advanced delivery technologies, which he built through internal development and acquisition and then successfully sold to Arakis Limited in 2004. He was also a Chairman and founder of Lotus Healthcare Corporation, an Asian-based fully integrated pharmaceutical company producing and marketing analgesics, cardiovascular and GI products in 35 cities of China. He was also CEO of Cell Systems Limited, a company focusing on medical applications of cryo-preservation and algal biotechnology, and Executive Vice President of a multibillion dollar trade and finance company based in New York. As a ministerial appointment in the US Government, Tom was a principal trade negotiator for the United States during the Tokyo Round. Tom represents the United Kingdom as a member of the EuropaBio Board of Directors. Tom holds an MBA from Harvard University, doctoral studies in molecular biology at the Max Planck Institute for Psychiatry in Munich and a degree in molecular biology from the Georgia Institute of Technology.
John Davis, Vincent, Sykes & Higham, Thrapston, Kettering, Northants, UK